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B-RafV600E oncogene mutation occurs most commonly in papillary thyroid carcinoma (PTC) and is associated
with tumor initiation. However, a genetic modification by B-RafV600E in thyrocytes results in oncogene-induced
senescence (OIS). In the present study, we explored the factors involved in the senescence overcome program in
PTC. First of all, we observed down-regulation of p-extracellular signal-regulated kinases 1/2 and up-regulation of
dual specific phosphatase 6 (DUSP6) in the PTC with B-RafV600E mutation. DUSP6 overexpression in vitro
induced extracellular signal-regulated kinases 1/2 dephosphorylation and inhibited B-RafV600E–induced
senescence in thyrocytes. Although DUSP6 protein was degraded by B-RafV600E–induced reactive oxygen
species (ROS), thyroid-stimulating hormone (TSH) stabilized DUSP6 protein by increasing Mn superoxide
dismutase expression and inhibited B-RafV600E–induced senescence. Although serum TSH was not increased, its
receptor was markedly upregulated in PTC with B-RafV600E. Furthermore, TSH together with DUSP6 reactivated
Ras signaling, resulted in activation of Ras/AKT/glycogen synthase kinase 3β, and stabilized c-Myc protein by
inhibiting its degradation. These observations led us to conclude that increased TSH signaling overcomes OIS and
is essential for B-RafV600E–induced papillary thyroid carcinogenesis.
Neoplasia (2014) 16, 1107–1120Introduction
Thyroid tumors are the most common endocrine malignancy, and
papillary thyroid carcinoma (PTC) accounts for more than 70% of all
thyroid cancers [1]. PTCs are known to frequently harbor activating
mutations in B-Raf kinase, among which the change of valine toglutamic acid at the residue 600 (B-RafV600E) is the most common
in PTCs [2,3]. B-RafV600E has also been reported in other cancers
such as melanoma and colorectal and ovarian cancers [4–7] and
known to be involved in early stage of carcinogenesis [4,5,8].
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normal cells, including human dermal fibroblasts, melanocytes, and
thyrocytes [9–11]. This phenomenon is called “oncogene-induced
senescence” (OIS), first identified by Serrano et al. [12]. OIS is
currently considered as a tumor-suppressive mechanism, which is
triggered in the face of aberrant Raf/mitogen activated protein kinase
kinase/Erk activation [13,14]. To overcome OIS and to undergo a
malignant transformation, therefore, additional stimuli such as tumor
suppressor gene inactivation, additional oncogene activation [15],
and attenuation or inactivation of aberrant Raf/mitogen activated
protein kinase kinase/Erk signaling are required [13,14]. Interesting-
ly, previous studies revealed no change of extracellular signal-
regulated kinases 1/2 (Erk1/2) phosphorylation in cancer tissues
from patients with B-RafV600E PTC [16,17], because phosphory-
lation of Erk1/2 is regulated by a negative feedback mechanism
[18,19] and dual specific phosphatases (DUSPs) are suggested to be
associated with a low level of phosphorylated Erk1/2 [20].
Furthermore, among DUSPs, up-regulation of DUSP6 has been
reported in PTC with B-RafV600E [16,21–23]. However, the role
and regulation mechanism of DUSP6 in B-RafV600E–induced
papillary thyroid carcinogenesis remain unclear.
In contrast to animal models of other cancers with B-RafV600E
[24–26], thyrocyte-specific expression of B-RafV600E was known to be
enough to induce PTC in transgenic mice [27,28]. However, animal
studies suggested the importance of thyroid-stimulating hormone (TSH)
signaling in B-RafV600E–induced thyroid carcinogenesis [27,29].
B-RafV600E could not induce any thyroid cancer if TSH is under normal
range, and B-RafV600E is expressed in postnatal thyroid, which is a
condition more similar to human sporadic PTCs [29]. However, it is
unclear how TSH signaling facilitates B-RafV600E tumorigenesis.
In the present study, therefore, we first investigated the effect of B-
RafV600E in normal isolated thyrocytes and compared the results
with those of human tissues from patient with B-RafV600E–positive
PTC. Furthermore, we analyzed the effect of TSH on B-RafV600E–
induced OIS in primary thyrocytes to test a hypothesis that TSH
signaling could abolish B-RafV600E–induced senescence. We found
that B-RafV600E–induced OIS could be overcome by up-regulation
of TSH signaling through the regulation of the DUSP6 activity.Materials and Methods
Tumor Samples from Patients
Fresh tissues from PTC were obtained from patients at Ajou University
Hospital after surgical resection with informed consent. Fresh tumor and
normal tissues were separately sampled in the representative areas by an
experienced pathologist and snap frozen in liquid nitrogen immediately
after resection, according to the specimen regulation of Ajou University
Hospital. Patients who had a past history of chemotherapy or radiation
therapy before the surgery were excluded from the study.
Cloning of B-RafV600E, DUSP6, and c-Myc and
Lentivirus Preparation
B-Raf wild-type, V600Emutant, c-Myc, andDUSP6were cloned from
normal thyroid and PTC in our laboratory. After insertion of cDNA into
the TOPO cloning vector (Invitrogen, Carlsbad, CA) and sequencing,
cDNAs were inserted into the pCDH-CMV-MCS-EF1-Puro lentivirus
vector (System Biosciences, Mountain View, CA). To generate lentiviral
particles, HEK-293TN cells were transfected with plasmid DNA (pGag-
pol, pVSV-G, and pCDH-B-Raf or pCDH-B-RafV600E) [30].Isolation and Culture of Thyrocytes
Normal and tumor thyrocytes were isolated from human tissues.
Briefly, thyroid tissue was cut into small pieces and washed five times
with phosphate-buffered saline (PBS). Enzymatic digestion was
carried out by adding 0.2% collagenase I (Worthington Biochemical,
Lakewood, NJ) in Hepes buffer (30 mM Hepes, 130 mM NaCl, 4
mM glucose, and 1 mM phosphate buffer), with gentle shaking for
6 hours at 32°C. The cells were centrifuged at 1500 rpm for
5 minutes and washed three times with PBS. The cell pellet was
resuspended in complete media (F12K; Gibco BRL, Bethesda, MD;
TSH, 10 mU/ml; insulin, 0.01 mU/ml; hydrocortisone, 10 nM;
transferring, 0.005 mg/ml; somatostatin, 10 ng/ml; glycyl-L-histidyl-L-
lysine acetate, 10 ng/ml; Sigma, St Louis, MO) and placed into 10-cm
tissue culture dishes. Immunocytochemical analysis detected two kinds
of thyrocyte-specific proteins including thyroglobulin and thyroid
transcription factor 1 (data not shown). SNU790 PTC cell line was
purchased from Korean Cell Line Bank (KCLB, Seoul, Korea).
Immunohistochemistry and Immunocytochemistry
Immunohistochemical staining was performed with primary
antibodies on 4-μm-thick representative tissue sections of formalin-
fixed paraffin-embedded tissue section in the Benchmark XT
automated immunohistochemistry stainer (Ventana Medical Systems
Inc, Tucson, AZ). The primary antibodies used were given as follows:
total Erk1/2, 1:700 and p-Erk1/2, 1:400 (Cell Signaling Technology,
Danvers, MA); B-RafV600E, 1:50 (Clone VE1; Spring Bioscience,
Pleasant, CA); c-Myc, 1:400; c-MycT58, 1:75; TSH receptor
(TSHR), 1:1500 (Abcam, Cambridge, MA); DUSP6, 1:1000
(Abnova, Walnut, CA); p16INK4A, predilution (Roche, Tucson,
AZ). Detection was done using the Ventana Optiview DAB Kit
(Ventana Medical Systems).
Thyrocytes were cultured on a cover glass, fixed with 4%
paraformaldehyde in PBS at 4°C for 20 minutes, and then washed
three times with PBS containing 0.1% Tween 20. Cells were
incubated with 1.5% horse serum in phosphate buffered saline
containing 0.1% tween 20 for 1 hour at room temperature, and anti–
p-Erk1/2 (Cell Signaling Technology), anti-TSHR (Abcam), or
anti–γ-tubulin (Sigma) was then applied overnight at 4°C. The
secondary antibody (1:500) was applied for 1 hour, and the cells were
observed under fluorescence microscope (Axio Imager M1; Carl
Zeiss, Oberkochen, Germany).
Analysis of B-RafV600E Mutation
We used three kinds of mutant analysis methods including
restriction fragment length polymorphism (RFLP), direct sequencing,
and immunohistochemistry. For genomic DNA isolation, one
representative formalin-fixed paraffin-embedded tissue block of
surgical specimens was selected and cut at 10-μm thickness. Genomic
DNA was extracted from manually microdissected tumor area of each
tissue section using a QIAamp DNA FFPE Tissue Kit (Qiagen,
Hilden, Germany) according to the manufacturer’s instruction. To
detect B-RafV600E mutation, we initially performed polymerase
chain reaction (PCR)–RFLP analysis [31]. The forward primer was
5′-TAAAAATAGGTGATTTTGGTCTAGCTCTAGCTCTAG-
3′, and the reverse primer was 5′-ACTATGAAAATACTATAGTT-
GAGA-3′. PCR was performed at 94°C for 30 seconds, 54°C for 30
seconds, and 72°C for 30 seconds for 35 cycles. After purification, the
PCR products were digested with XbaI for 90 minutes, electropho-
resed, and stained with ethidium bromide. The presence of B-
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bands. In case of negative or equivocal results for the B-RafV600E
mutation with the RFLP method, we performed additional direct
sequencing. Briefly, B-Raf exon 15 was amplified by PCR using the
forward primer 5′-GCTTGCTCTGATAGGAAAATGAG-3′ and re-
verse primer 5′-GTAACTCAGCAGCATCTCAGG-3′. PCR was
performed at 94°C for 30 seconds, 60°C for 30 seconds, and 72°C for
30 seconds for 34 cycles. After amplified products were purified, direct
DNA sequencingwas performedbyAppliedBiosystems 3500XLGenetic
Analyzer with GeneMapper® Software v4.1 (Applied Biosystems, Foster
City, CA). In addition to molecular analysis, we also performed
immunohistochemical analysis using a mutation-specific monoclonal
antibody, VE1, which was developed by Capper et al. [32].
Immunoprecipitation-Phosphatase Activity Assay
Immunoprecipitation (IP) with anti-DUSP6 IgG was performed
with normal and B-RafV600E with or without TSH-treated
thyrocyte lysate in a solution containing 20 mM Tris-HCl (pH
7.0), 1% Triton X-100, 0.25 M sucrose, 1 mM EDTA, 1 mM
EGTA, 0.1% β-mercaptoethanol, 1 mM PMSF, and 1 μg/ml
leupeptin by the standard method. DUSP6-IP-phosphatase assay
mixture (200 μl) containing the above DUSP6 immunoprecipitates
and 20 mM p-nitrophenyl phosphate in 50 mM succinate buffer was
incubated at 37°C for 30 minutes, and the phosphate released was
measured with an enzyme-linked immunosorbent assay reader
(BioTek, Winooski, VT) at 405 nm.
Measurement of Ras Activity
GTP-bound Ras was incubated with Rho binding protein agarose
conjugate (Millipore, Billerica, MA) for 30 minutes at 4°C in normal,
B-RafV600E, B-RafV600E/DUSP6, SNU790, and SNU790/
shDUSP6 cell lysates with or without TSH treatment for 5, 15,
and 30 minutes. The bead was washed twice with washing buffer and
dissolved in 2× sodium dodecyl sulfate (SDS) sample buffer, and then
SDS–polyacrylamide gel electrophoresis was carried out. GTP-Ras
was detected with anti-Ras (Millipore) antibody. Positive and
negative controls were treated with 10 mM GTPγS or 100 mM
guanosine diphosphate for 30 minutes, respectively.
Real-Time PCR Analysis
Total cellular RNAs were isolated from normal and PTC tissues.
First-strand cDNA was synthesized by reverse transcription reaction
using oligo-dT primers from 1 μg of total cellular RNA. Real-time
PCR was carried out with Power SYBR Green PCR Master Mix
(Applied Biosystems) using the following conditions: initial activation
at 95°C for 5 minutes, followed by 40 cycles of 95°C for 15 seconds
and 60°C for 1 minute. The primers used for real-time PCR
were given as follows: Mn superoxide dismutase (SOD): 5′-
GACCTGCCCTACGACTACG-3′, 5′-TGACCACCACCATT-
GAACTT-3′; glutathione peroxidase-1 (GPx1): 5′-TTCCCGTG
CAACCAGTTTG-3′, 5′-TTCACCTCGCACTTCTCGAA-3′;
Cu/Zn SOD: 5′-AGGGCATCATCAATTTCGAG-3′, 5′-
TGCCTCTCTTCATCCTTTGG-3′; catalase: 5′-TTTCCCAG
GAAGATCCTGAC-3′, 5′-ACCTTGGTGAGATCGAATGG-3′;
thiol-specific antioxidant: 5′-CCAGACGCTTGTCTGAGGAT-3′, 5′-
ACGTTGGGCTTAATCGTGTC-3′; DUSP6: 5′-GAGTCT-
GACCTTGACCGAGACCCC-3′, 5′-TTCCTCCAACACGTC
CAAGTTGGT-3′; Ets1: 5′-CTGCGCCCTGGGTAAAGA-3′, 5′-
CCCATAAGATGTCCCCAACAA-3′; c-Myc: 5′-GCCACGTCTCCACACATCAG-3′, 5′-TGGTGCATTTTCGGTTGTTG-3′;
p16INK4A: 5′-CTGCCCAACGCACCGAATAG-3′, 5′-TACCGTGC
GACATCGCGATG-3′; TSHR: 5′-CCCAGCTTACCGCCCAGT-3′,
5′-TAGAAAATGCATGACTTGGAATAGTTC-3′; β-actin: 5′-
CCCTGGCACCCAGCAC-3′, 5′-GCCGATCCACACGGAGTAC-
3′, respectively.
Measurement of Reactive Oxygen Species
Intracellular reactive oxygen species (ROS) was measured by using
oxidation-sensitive fluorescent probe dichlorodihydrofluorescein
diacetate (DCF-DA). Thus, thyrocytes or SNU790 cells were treated
with DCF-DA (20 μM) for 10 minutes, and the cells were collected
and washed with PBS. They were then transferred to 5-ml polystyrene
round bottom tubes and subjected to flow cytometry (BD FASCanto
II; BD Biosciences, San Jose, CA) for acquisition and analysis.
RNA Interference
For knockdown of DUSP6, TSHR, and B-Raf expression, shRNA
was prepared in a pLKO lentiviral vector (Sigma) and then amplified
in 293TN cells. Thyrocytes were plated and grown in 60-mm culture
dishes. After overnight culture, they were infected with either target
shRNA or a nonsilencing control shRNA. After infection of the
lentivirus, the cells were selected for 1 to 2 weeks at a concentration of
3.5 μg/ml puromycin. shRNA sequences were given as follows: shB-
Raf: 5′-TTACCTGGCTCACTAACTAAC-3′; shTSHR: 5′-
GTTAGGCTACCAGCATATTTG-3′; shDUSP6: 5′-TCTAATC-
CAAAGGGTATATTT-3′, respectively.
Senescence-Associated β-Galactosidase Staining
The cells or frozen tissue slides were fixed with 10% formalin for 10
minutes and then incubated with SA-β-gal solution (X-gal, 1 mg/ml;
40 mM citric acid/sodium phosphate, pH 6.0; 5 mM potassium
ferrocyanide; 5 mM potassium ferricyanide; 150 mM NaCl; 2 mM
MgCl2) for 10 hours at 37°C. After washing with PBS, SA-β-gal–
positive cells were then analyzed under light microscopy.
Analysis of DUSP6 Protein Stability
To evaluate the stability of the DUSP6 protein, control or B-
RafV600E–expressing thyrocytes were treated with cycloheximide
(25 μg/ml) at indicated times. The cell lysates were prepared and
analyzed by Western blot analysis after separation on SDS–
polyacrylamide gel electrophoresis. The band intensity was analyzed
by a densitometer and represented as a score.
Statistical Analysis
Numerical data are presented as mean + SD of independent
determinations. Statistical analysis of differences was performed by
Student's t test, and a P value b0.05 was considered as significant.
Results
B-RafV600E Induces OIS in Primary Thyrocytes
We generated lentivirus harboring B-RafV600E to express the
mutant protein in isolated primary thyrocytes and found cellular
enlargement and elongation with cytoplasmic vacuoles in the cells.
These morphologic findings were consistent with cellular senescence
but not transformation (Figure 1A). Furthermore, the results of
growth analysis, SA-β-gal staining, and p16INK4A mRNA analysis
were compatible with cellular senescence in B-RafV600E–expressing
thyrocytes (Figure 1B). Western blot analysis revealed that B-
Figure 1. B-RafV600E induces OIS in isolated normal thyrocytes. (A) B-RafV600E–induced OIS in isolated normal thyrocytes. Normal
thyrocytes were infected with control or B-RafV600E lentivirus and selected with puromycin for 1 week. The inset represents higher
magnification field. (B) Expression of SA-β-gal and p16INK4A was higher in B-RafV600E–expressing cells than in control. (C) Western blot
analysis of B-Raf, p-Erk1/2, and AKT. Normal thyrocytes were infected with control, B-Raf wild-type, or B-RafV600E lentivirus, selected
with puromycin for 1 week and then subjected to Western blot analysis. (D) Immunocytochemical analysis of p-Erk1/2 in normal and B-
RafV600E–expressing thyrocytes. After epidermal growth factor treatment, translocation of p-Erk1/2 was analyzed in control or B-
RafV600E lentivirus–infected thyrocytes, respectively.
1110 TSH Signaling in Papillary Thyroid Carcinogenesis Kim et al. Neoplasia Vol. 16, No. 12, 2014
Figure 2. Cancer cells in B-RafV600E PTC tissues escape from senescence. (A) SA-β-gal–positive cancer cells were observed in B-
RafV600E–harboring PTC tissue. Upper and lower panels show SA-β-gal and SA-β-gal/hematoxylin staining, respectively. (B) p16INK4A
expression in B-RafV600E–harboring PTC tissues. (C) Ki67 expression in B-RafV600E–harboring PTC tissues. Phosphorylated Erk1/2
expression was analyzed by immunohistochemistry (D) and Western blot analysis (E). Normal and B-RafV600E PTC regions were serially
sectioned and stained with B-RafV600E, Erk1/2, and p-Erk1/2, respectively. Fifty or 30 cases each of B-RafV600E PTC were analyzed with
immunohistochemistry and Western blot analysis, respectively, and the expression level of p-Erk1/2 is presented as a table. (F) DUSP6
expression in PTC tissue was analyzed by real-time PCR andWestern blot analysis. Twelve and 30 cases each of normal and B-RafV600E–
harboring PTC regions were analyzed for DUSP6 mRNA and protein, respectively. Representative Western blot data are shown in this
figure, and total cases of DUSP6 protein expression pattern are presented as a table in Figure 5. (G) Up-regulation of DUSP6 in RafV600E–
harboring PTC tissues. Fifty cases of B-RafV600E PTC were analyzed for DUSP6 expression by immunohistochemistry, and the
expression pattern of DUSP6 is presented as a table. The inset represents higher magnification field. N and T indicate normal and cancer,
respectively.
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examined epidermal growth factor–induced phosphorylation and
translocation of Erk1/2 and found that Erk1/2 was translocated into
the nucleus only in normal thyrocytes, but not in B-RafV600E–
transduced thyrocytes (Figure 1D). These data clearly indicated that
B-RafV600E induced OIS in primary normal thyrocytes.Cancer Cells in B-RafV600E PTC Tissues Escape from OIS
Next, we analyzed the role of B-RafV600E mutation in PTC
tissues. Senescence has been found in the pre-malignant stage of
tumor but not in malignant tumor [15,33,34]. However, we found
that some of the cancer cells in B-RafV600E PTC tissues revealed
SA-β-gal and p16INK4A immunopositivity (Figure 2, A and B),
Neoplasia Vol. 16, No. 12, 2014 TSH Signaling in Papillary Thyroid Carcinogenesis Kim et al. 1113whereas some remaining cancer cells showed proliferation activity
(Figure 2C). These findings suggested that senescence program was in
progress in papillary thyroid carcinogenesis, and senescence as well as
the cells that escaped from senescence co-existed in B-RafV600E
PTC tissue. Furthermore, we observed that Erk1/2 phosphorylation
was not increased in most of B-RafV600E PTCs (46/50 cases; 92%),
despite the fact that B-RafV600E protein was highly expressed
(Figure 2, D and E). Low level of Erk1/2 phosphorylation in PTC
patient tissues has already been reported [16,17,23]. Thus, these data
are consistent with previous publications data. This finding reflects
that dephosphorylation of p-Erk1/2 actively occurred by phosphatase
in B-RafV600E–harboring PTC [16,18–20]. Since previous studies
reported increased expression of DUSP6 in PTC [16,21–23], we
examined DUSP6 expression in B-RafV600E PTC tissues and found
an up-regulation of DUSP6 (Figure 2, F andG). Moreover, as shown in
the right panel of Figure S1, Erk1/2 phosphorylation was markedly
downregulated in B-RafV600E–expressing cells when DUSP6 was
lentivirally transferred. These data indicated that, in B-RafV600E PTC
tissues, Erk1/2 phosphorylation could not bemaintained due to DUSP6.
Therefore, we next investigated the mechanisms involved in the
dephosphorylation of p-Erk1/2 by DUSP6 in both B-RafV600E–
harboring PTC tissues and isolated B-RafV600E–transduced thyrocytes.
TSH Increases DUSP6 Expression through Regulation of
ROS Generation
Erk1/2 phosphorylation and DUSP6 expression are reciprocally
regulated; DUSP6 expression is controlled by Erk1/2-Ets1 signaling,
and expressed DUSP6 dephosphorylates p-Erk1/2 by feedback
mechanism [18,19]. Indeed, Figure S2 shows up-regulation of Ets1
transcription factor in B-RafV600E PTC. Although DUSP6 mRNA
expression in B-RafV600E–transduced thyrocytes was higher than
normal cells, its protein expression and phosphatase activity were
almost similar to those of normal thyrocytes (Figure 3A). In support
of a recent study that DUSP6 was rapidly degraded in proteasome
[35], we found that DUSP6 protein was rapidly degraded in B-
RafV600E–transduced thyrocytes and stabilized by MG132 protea-
somal inhibitor (Figure 3B). To exclude the possibility of DUSP6
degradation by autophagy, thyrocytes were treated with 3-methyla-
denine or E64d/pepstatin A; however, DUSP6 protein was not
accumulated by autophagy inhibitors (Figure S3). In addition, we
analyzed ROS generation because DUSP6 has been shown to be
inactivated and degraded by ROS [35,36] and found marked up-Figure 3. TSH increased DUSP6 activity. (A) B-RafV600E increased D
activity (right panel). Thyrocytes were infected with control or B-RafV6
IP-phosphatase assay. Bar graph represents more than three indepen
expressing thyrocytes. Thyrocytes were treated with cycloheximide (C
for DUSP6 protein expression (upper panel). Thyrocytes were treated w
analyzed by Western blot analysis (lower panel). Number represents
actin ratio compared with untreated data. (C) TSH inhibited ROS gener
were treated with or without TSH (1 mU/ml) for 72 hours, and ROS ge
independent experiments. (D) DUSP6 expression in TSH-treated (1
measured by real-time PCR andWestern blot analysis. Number indica
expression in NAC-treated (5 mM, 24 hours) thyrocytes (right panel).
DUSP6 activity. DUSP6 activity was measured in B-RafV600E–expre
Lower immunoblot figure shows immunoprecipitated DUSP6. (F) TS
proteins was analyzed by real-time PCR and Western blot with or with
panel) and B-RafV600E–expressing thyrocytes (lower panel), respec
Twelve each of B-RafV600E mutant PTC and normal tissues were anregulation of ROS generation in B-RafV600E–transduced thyr-
ocytes (Figure 3C). These data provided evidence that DUSP6 is
likely inactivated, despite the fact that the level of DUSP6 mRNA
was elevated in B-RafV600E–transduced thyrocytes and that
reactivation or stabilization of DUSP6 are required to induce low
level of p-Erk1/2 in PTC. Next, the effect of TSH on DUSP6 was
investigated in B-RafV600E–expressing thyrocytes, since the
dependency of B-Raf carcinogenesis of thyroid on TSH signaling
has been demonstrated in genetically engineered mouse models [29].
Although TSH itself could not increase DUSP6 mRNA expression,
slight increases in protein expression and the activity of phosphatase
were observed in TSH-treated thyrocytes (Figure 3, D, left, and E).
Next, we investigated ROS generation under the influence of TSH
and found a decrease in ROS generation in B-RafV600E–expressing
thyrocytes by TSH stimulation (Figures 3C and S4). To further
confirm the ROS effect on DUSP6 expression, we employed N-
acetylcysteine (NAC) to scavenge ROS and found that DUSP6
protein expression was increased by NAC without up-regulation of
DUSP6 mRNA (Figure 3D, right panel). Since ROS generation was
downregulated for 72 hours after TSH treatment (Figure S4), and
TSH increased DUSP6 activity through regulation of ROS, we
examined the expression of ROS scavenger proteins, such as
catalase, Mn SOD, Cu/Zn SOD, GPx1, and thiol-specific
antioxidant, and found that TSH increased Mn SOD expression
(Figure 3F). We further analyzed antioxidant proteins mRNA
expression in PTC by real-time PCR and found up-regulation
of GPx1 and Mn SOD (Figure 3G). These data indicated that
DUSP6 could be reactivated by TSH through the regulation of
ROS generation.
TSH Signaling Inhibits B-RafV600E–Induced Senescence
through DUSP6
Next, we evaluated the effect of DUSP6 on B-RafV600E–induced
senescence using B-RafV600E/DUSP6 co-transduced thyrocytes.
Figure 4, A and B, show significant reduction in the expression of
SA-β-gal and p16INK4A in B-RafV600E/DUSP6 co-transduced
thyrocytes, indicating that DUSP6 overexpression inhibited OIS in
the thyrocytes. These data led us to the hypothesis that reactivated
DUSP6 by TSH could inhibit B-RafV600E–induced OIS. To verify
this, we examined normal and B-RafV600E–transduced thyrocytes
after TSH treatment. As expected, TSH treatment increased
proliferation of normal and B-RafV600E–transduced thyrocytesUSP6 mRNA expression (left panel) but not protein expression and
00E lentivirus for 1 week, and then DUSP6 activity was analyzed by
dent experiments. (B) DUSP6 was degraded rapidly in B-RafV600E–
HX, 25 μg/ml) to inhibit translation at indicated times and analyzed
ith MG132 (10 μM) at indicated times and DUSP6 stabilization was
average of three independent experiments and indicates DUSP6/
ation in B-RafV600E–expressing cells. Normal and B-RafV600E cells
neration was measured by FACS analysis. Bar graph represents five
mU/ml, 72 hours) thyrocytes (left panel). DUSP6 expression was
tes the ratio of DUSP6 to actin. The arrow indicates DUSP6. DUSP6
Number indicates the ratio of DUSP6 to actin. (E) TSH reactivated
ssing cells with or without TSH (1 mU/ml) treatment for 72 hours.
H induced Mn SOD expression. The expression of ROS scavenger
out TSH (1 mU/ml, 24 hours) treatment in normal thyrocytes (upper
tively. (G) Mn SOD expression was upregulated in PTC tissues.
alyzed for mRNA of ROS scavenger proteins by real-time PCR.
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(Figure 4, D and E), consistent with the result in Figure 3; TSH
decreased ROS generation by regulation of Mn SOD expression and
increased DUSP6 activity.
We then investigated the status of TSH in patients with B-
RafV600E PTC, since we observed above that upregulated TSH
signaling was an important factor to overcome B-RafV600E–induced
senescence in thyroid carcinogenesis. However, no patients with B-
RafV600E PTC showed a significant elevation of serum TSH (serum
TSH range of patients: 0.19–5.56, average: 1.85, normal range:
0.35–5.5 mU/l; Figure 4F, left panel). We next examined the
expression of TSHR in B-RafV600E–harboring PTC tissues and
found diffuse strong immunoreactivity for TSHR in the cytoplasm as
well as in the membrane of cancer cells, whereas there is only focal
membranous staining in normal follicles (Figure 4F, right panel). To
exclude the possibility of nonspecific antibody reaction, we analyzed
TSHR mRNA expression in B-RafV600E PTC and found a
moderate increase in TSHR mRNA expression (0.64- to 2.98-fold,
1.71 + 0.74, n = 23, P b .01; Figure S5). We further accessed the
effect of B-RafV600E on TSHR expression using cultured primary
thyrocyte model. Real-time PCR and immunocytochemical analyses
revealed that B-RafV600E increased the expression of TSHR in
thyrocytes (Figure 4G). These data suggested that TSH signaling by
its receptor overexpression could inhibit OIS in B-RafV600E PTC.
Although TSH inhibited OIS in thyrocytes, the cells were not
transformed in vitro. Therefore, our data raise the possibility of
additional mechanism involved in papillary thyroid carcinogenesis.
Ras/AKT/c-Myc Signaling Is Reactivated by TSH and DUSP6
Inhibition of Ras activity by p-Erk1/2 is a well-characterized
feedback signaling [37]. Phosphorylated Erk1/2 by B-RafV600E
inhibited Ras-dependent AKT activation (Figure 5A, left pathway).
However, in the presence of active DUSP6, p-Erk1/2 was unable to
inhibit Ras any more, and Ras/AKT signaling was reactivated by
ligand-receptor signaling (Figure 5A, right pathway). Indeed,
reactivation of Ras (Figure 5B) and AKT phosphorylation were
induced by TSH treatment in the presence of DUSP6 (Figure 5C).
We further confirmed the feedback inhibition loop by inhibition of
B-Raf. AKT phosphorylation was increased by a B-Raf inhibitor in B-
RafV600E–expressing thyrocytes (Figure S6). Furthermore, when
cancer cells from the B-RafV600E–harboring PTC were used, AKT
signaling was activated by TSH (Figure 5D).Figure 4. TSH signaling inhibits B-RafV600E–induced senescence. (A)
lentivirus was co-infected with or without DUSP6 lentivirus and selec
analyzed with SA-β-gal staining. p16INK4A expression was analyzed in
panel) and Western blot analysis (lower panel) (B). All of the bar graph
proliferation in normal and B-RafV600Emutant expressing thyrocytes.
selected with puromycin for 1 week; 3 × 103 cells were seeded with o
(D) TSH inhibited B-RafV600E–induced OIS. Normal thyrocytes were
3.5 μg/ml puromycin for 2 weeks with or without TSH, and senesce
expression in B-RafV600E–expressing cells with or without TSH (1 mU
PTC patients. Serum TSH level was analyzed in 31 B-RafV600E–harbo
in B-RafV600E–harboring PTC (right panel). The inset shows h
immunohistochemistry in 50 cases of B-Raf mutant–type PTC, and
up-regulation of TSHRmRNA in thyrocytes. TSHR expression was ana
infected with control, B-RafV600E, B-RafV600E/shB-Raf, or B-RafV60
real-time PCR. In the case of the B-Raf inhibitor study, B-RafV600E–in
and then analyzed. N and T indicate normal and cancer, respectivelyAKT signaling can activate several oncoproteins including c-Myc
[38]. To test whether c-Myc could be activated by AKT signaling, we
examined c-Myc expression in B-RafV600E PTC. However, c-Myc
mRNA expression was found to be almost similar to that in normal
thyroid region. Nevertheless, immunohistochemical staining and
Western blot data showed higher protein expression of c-Myc in B-
RafV600E PTC (Figure 5E), suggesting that up-regulation of c-Myc
protein could be associated with a posttranslational event but not
transcription. Therefore, the stability of c-Myc protein was evaluated
by determining phosphorylation status on its Thr58 residue, since it is
induced by GSK3β and phosphorylation on Thr58 residue of c-Myc
increases its degradation by ubiquitination [39]. Figure 5F shows that
TSH slightly decreased c-MycT58 phosphorylation in B-RafV600E/
DUSP6 but not in B-RafV600E only expressing cells. When c-Myc
protein level was measured in cells treated with TSH for 24 hours,
marked up-regulation of c-Myc was found in B-RafV600E/DUSP6
expressing thyrocytes (Figure 5F, lower panel). In vivo PTC tissue data
clearly showed stabilization of c-Myc protein (Figure 5, G and H).
These data suggested that Ras/AKT signaling reactivated by DUSP6
and TSH induced c-Myc stabilization and that stabilized c-Myc might
be involved in thyroid carcinogenesis.
We further confirmed the effect of TSH signaling using B-
RafV600E PTC cell lines (SNU790). Surprisingly, knockdown of
TSHR induced down-regulation of cell proliferation (20% decrease,
data not shown) along with an increase in ROS generation
(Figure 6A) and a decrease in DUSP6 expression in the presence of
TSH (Figure 6B). Furthermore, inhibition of DUSP6 by shRNA
increased p-Erk1/2 expression and inhibited TSH-induced Ras
activation (Figure 6, C and D). These data suggested that TSHR
signaling is also important in maintaining malignant phenotype in
established B-RafV600E cancer cell line.
Discussion
It is well established that OIS induction occurs when the oncogene is
overexpressed [40,41]. In the present study, we evaluated the effects
of B-RafV600E proteins, which are driven by a cytomegalovirus
(CMV) promoter in the isolated thyrocytes by comparing with that
of normal endogenous promoter in the B-RafV600E PTC. We
found senescence program undergoing in both thyrocytes and PTC.
Furthermore, some of thyrocytes in PTC tissue harboring B-
RafV600E were found to undergo senescence program, whereas
others escaped, strongly suggesting that senescence escape programDUSP6 inhibited B-RafV600E–induced OIS. Control or B-RafV600E
ted with 3.5 μg/ml puromycin for 2 weeks. Senescence cells were
B-RafV600E and DUSP6 co-infected cells by real-time PCR (upper
s represent five independent experiments. (C) TSH accelerated cell
Thyrocytes were infected with control or B-RafV600E lentivirus and
r without TSH, and the cell number was counted at indicated times.
infected with control or B-RafV600E lentivirus and selected with
nce cells were then analyzed with SA-β-gal staining. (E) p16INK4A
/ml) was analyzed by real-time PCR. (F) TSH and TSHR expression in
ring PTC patients (left panel). Marked elevation of TSHR expression
igher magnification field. TSHR expression was analyzed by
the expression level is presented (table). (G) B-RafV600E induced
lyzed by real-time PCR and immunocytochemistry. Thyrocytes were
0E/shTSHR for 1 week and then analyzed for TSHR expression by
fected thyrocytes were treated with PLX4032 (20 μM) for 24 hours
.
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Figure 6. Effect of TSH signaling on SNU790 B-RafV600E PTC cell lines. (A) Knockdown of TSHR increased ROS generation. SNU790 cells
were infected with shTSHR lentivirus for 1 week in the presence of TSH (1 mU/ml) and analyzed for TSHR expression by real-time PCR (left
panel) and ROS generation (right panel). Bar graph indicates three independent experiments. (B) Knockdown of TSHR decreased DUSP6
protein expression. SNU790 cells were harvested under the same conditions as in A and then analyzed for DUSP6 and p-Erk1/2
expressions by real-time PCR and Western blot. (C) Knockdown of DUSP6 increased p-Erk1/2 expression. SNU790 cells were infected
with shB-Raf or shDUSP6, selected with puromycin for 1 week, and then analyzed for p-Erk1/2, B-Raf, and DUSP6 by Western blot
analysis. Reactivation of p-Erk1/2 is shown in shDUSP6-expressing cells. (D) Knockdown of DUSP6 did not activate Ras signaling.
SNU790 cells were infected with shDUSP6, selected with puromycin for 1 week, and then changed with serum-free media for 24 hours
and treated with 1 mU/ml TSH at indicated times and analyzed for GTP-bound Ras by immunoblot.
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study, therefore, we first focused on factors involving dephosphor-
ylation of Erk1/2 in PTC, since we observed a clear difference of
p-Erk1/2 between B-RafV600E–expressing thyrocytes and B-
RafV600E–harboring PTC, and recent studies showed thatFigure 5. DUSP6 and TSH reactivated Ras/AKT signaling in B-RafV600
AKT or mitogen activated protein kinase pathway. (B) Reactivation of
RafV600E, or B-RafV600E/DUSP6 lentivirus and selected with purom
before TSH treatment for 24 hours. The cells were harvested after trea
Ras protein was analyzed by Rho binding protein binding assay. (C) R
were infected with control, B-RafV600E, or B-RafV600E/DUSP6 len
changed with serum-free media before treatment of TSH for 24 hour
indicated times and then subjected to Western blot analysis. (D) AKT p
cells were treated with TSH (1 mU/ml) at indicated times, and p-AKT an
c-Myc expression was analyzed by real-time PCR, Western blot analy
RafV600E were analyzed for immunohistochemistry, and the expre
magnification field. (F) TSH increased c-Myc protein expression. T
harvested time-dependently (0, 1, 2, 4, and 6 hours) and analyzed f
protein expressions by Western blot analysis (upper panel). Thyrocytes
thenharvestedand analyzed for p-Erk1/2, c-Myc, andDUSP6. (G)Weste
normal and B-RafV600E–harboring PTC region were analyzed, and t
analysis of c-MycT58 phosphorylation in PTC. Fifty cases each of norma
expression is presented (table). The inset shows higher magnificationattenuation or depletion of p-Erk1/2 could prevent the activation
of Ras-induced OIS [13,14]. We found that Erk1/2 dephosphor-
ylation was induced by DUSP6 and that DUSP6 was markedly
upregulated in human B-RafV600E PTC tissues in agreement with
previous studies [16,17,21–23]. Although B-RafV600E induced up-E–expressing thyrocytes. (A) Schematic drawing of TSH/TSHR/Ras/
Ras by DUSP6 and TSH. Thyrocytes were infected with control, B-
ycin for 2 weeks. The cells were changed with serum-free media
tment with TSH (1 mU/ml) at indicated times, and then GTP-bound
as/AKT signaling was reactivated by DUSP6 and TSH. Thyrocytes
tivirus and selected with puromycin for 2 weeks. The cells were
s. The cells were harvested after treatment with TSH (1 mU/ml) at
hosphorylation in B-RafV600E harboring isolated PTC cells. Cancer
d p-Erk1/2 expressions were analyzed. (E) c-Myc expression in PTC.
sis, and immunohistochemistry. Fifty cases each of normal and B-
ssion level of c-Myc is presented (table). The inset shows higher
hyrocytes were treated with 1 mU/ml TSH, and they were then
or c-Myc, c-MycT58, and p-glycogen synthase kinase 3β (GSK3β)S9
were treated with or without TSH (1 mU/ml) for 24 hours and were
rnblot analysis ofDUSP6, c-Myc, andp-GSK3βS9. Thirty cases eachof
he expression level is presented (table). (H) Immunohistochemical
l and B-RafV600E were analyzed for immunohistochemistry, and the
field. N and T indicate normal and cancer, respectively.
Figure 7. TSH/TSHR signaling together with B-RafV600E induced PTC cooperatively.
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[42]. As a result, DUSP6 could be degraded and inactivated. Under the
influence of TSH stimulation, the expression of Mn SOD scavenged
ROS sufficiently and was able to reactivate the DUSP6 activity.
Degl'Innocenti et al. reported overexpression of DUSP6 in PTC and
poorly differentiated carcinoma [22]; however, overexpression of
DUSP6 failed to decrease p-Erk1/2 in poorly differentiated carcinoma,
which was associated with decreased expression of TSHR [43,44]. This
finding also provides evidence supporting that reactivation of DUSP6
depends on TSH signaling.
It has been suggested that TSH stimulation is required to develop
PTC in the B-RafV600E transgenic model [27,28]. Several
epidemiologic studies also suggest a strong association between
TSH levels and risk of malignancy in thyroid, although serum TSH
levels in most of the patients with PTC were within normal ranges
[45–47], similar to our present result. Previous studies showed that
TSHR expression was downregulated in thyroid cancers [43,44]. In
the present study, however, we observed increased expression of
TSHR in B-RafV600E PTC. In addition, we also found increased
expression of TSHR in the B-RafV600E–expressing thyrocytes. We
cannot clearly explain these discrepancies between our results and
previous observation; nevertheless, we cautiously suggest that these
differences might be due to differentiation of tumor cells, because
down-regulation of TSHR is observed more frequently in poorly
differentiated and undifferentiated carcinomas [43,44]; however, all
of the PTCs in the present study were pathologically well-
differentiated PTCs. Indeed, increased protein expression of TSHR
in PTC has been reported previously [43,48,49]. In addition, several
clinical studies reported that serum TSHR mRNA was increased in
patients with PTC, but not in patients with benign nodules, and that
serum TSHR mRNA could be detected in about 80% of the patients
[50,51]. These data indicate that the increase in TSHR mRNA is not
uncommon in PTC. Although it has been suggested that B-
RafV600E–positive thyroid cancer is associated more frequently
with methylation of TSHR gene promotor [52], earlier data on direct
correlation between protein expression and mRNA of TSHR are very
limited [49]. Therefore, further study is needed to clarify the
mechanisms involved in the increase in TSHR in B-RafV600E PTC.
An extensive activation of p-Erk1/2 can inhibit Ras activation [37].
However, Ras activation by TSH in thyrocytes still remainscontroversial. In Wistar rat thyroid cells, TSH stimulates cell
proliferation through cAMP-mediated Ras activation [53]; however,
contradictory data have also been reported in dog primary thyrocytes
[54], not being fully evaluated in primary human thyrocytes. It is
highly possible that TSH can activate Ras through cAMP-mediated
pathway in human primary thyrocytes.
Our in vitro data showed that Ras/AKT pathway was downreg-
ulated in B-RafV600E–expressing cells compared with normal
thyrocytes. Overexpression of DUSP6 inhibited p-Erk1/2. Moreover,
reactivated Ras had a potential to activate the phosphoinositide 3-
kinase pathway. However, our present data indicated that the effects
of reactivation of DUSP6 and TSH were limited to the inhibition of
OIS, and further transformation signaling seems to be required to
develop PTC. At that point, therefore, we focused on c-Myc
expression in PTC. Although c-Myc mRNA level was not changed,
protein level seemed to be controlled by a posttranslational event.
These results led us to suggest the possibility that reactivation of
Ras/AKT signaling by TSH and DUSP6 involves GSK3β phosphor-
ylation, which in turn induces c-Myc stabilization and represents as
an overexpression of c-Myc.
At this point, we asked a question of what is the role of B-
RafV600E mutation in papillary thyroid carcinogenesis. First,
B-RafV600E is associated with TSHR overexpression in early stage
of thyroid carcinogenesis. Higher expression of TSHR is a unique
phenotype of B-RafV600E PTC. We also analyzed the expression of
TSHR in the B-Raf wild-type PTC and found that the immunoex-
pression of TSHR was not as strong as that of B-RafV600E–
harboring PTCs (Figure S7). The present results suggest that
TSH/TSHR signaling helps cells escape from OIS through down-
regulation of ROS and activation of DUSP6. Second, B-RafV600E
induces chromosomal instability. We found that the cell cycle was
blocked at the S phase (data not shown) and centrosome number was
markedly increased by B-RafV600E, resulting in aneuploid formation
(Figure S8). We did not include it in the Results section, because
these phenotypes have already been observed by Liu et al. [55] and
Mitsutake et al. [56]; Liu et al. suggested that Msp1 phosphorylated
by B-RafV600E contributes to chromosome instability in melanoma
[55]. Therefore, our experimental results together with the above-
mentioned studies suggest that B-RafV600E could initiate cancer
formation by regulation of chromosome stability.
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oncogene or combined tumor suppressor gene inactivation; “two or
multiple hits” are required for cancer formation. However, B-
RafV600E expression is enough to induce PTC [27], suggesting that
“one hit; B-RafV600E” is enough to develop a cancer in the thyroid.
Since senescence is a good barrier to develop a cancer, it is highly
possible that B-RafV600E mutation can develop a cancer in the
thyroid if a program to overcome senescence co-exists. Therefore, our
present data strongly suggest that OIS was overcome by hormone
stimulation in the absence of additional oncogene or tumor
suppressor gene dysregulation. We could not perform a cancer
formation assay such as nude mouse injection, because one-oncogene
activation and hormonal stimulation are not strong inducers for
cancer development. We also tried double lentivirus delivery into
thyrocytes, including B-RafV600E/c-Myc with TSH. Although we
found some of these cells with morphologic changes that were consistent
with the transformation (Figure S9), we could not carry out further
observation because of massive cell death. Consequently, we could not
fully explain the exact mechanism involved in papillary thyroid
carcinogenesis. Nevertheless, we cautiously suggest that B-RafV600E
mutation and TSH signaling cooperatively induced PTC (Figure 7).
Conclusion
We herein showed that B-RafV600E and TSH cooperatively play
critical roles in papillary thyroid carcinogenesis and suggest that
inhibition of B-RafV600E together with TSHR can inhibit tumor
progression more efficiently in B-RafV600E–harboring PTC.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.neo.2014.10.005.
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